VERTEX PHARMDRNVERTEX PHARMDRNVERTEX PHARMDRN

VERTEX PHARMDRN

No trades
See on Supercharts

Key facts today

Redburn Atlantic has adjusted the price target for Vertex Pharmaceuticals to $570 from $560, while analysts polled by FactSet report an average rating of overweight and a mean price target of $523.24.
Analyze the impactAnalyze the impact
Market capitalization
‪667.30 B‬BRL
−0.00BRL
‪18.08 B‬BRL
‪49.14 B‬BRL
Beta (1Y)
−0.10

About Vertex Pharmaceuticals Incorporated


CEO
Reshma Kewalramani
Headquarters
Boston
Website
Founded
1989
ISIN
BRVRTXBDR001
FIGI
BBG00P14KF71
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.